Pluristem Therapeutics, Inc. (PSTI) is Commercializing Profound New Approach to Therapeutics

There are so many significant developments occurring in the medical industry on a regular basis that it’s almost impossible for an investor to separate out those that are truly profound and have long term implications. Some companies, however, are doing things that are clearly in that camp, developing therapeutic approaches that could revolutionize the treatment and prevention of whole classes of diseases.

Pluristem Therapeutics is a bio-therapeutic company working with what are called allogenic (unrelated donor-patient) cell therapy products. The company is creating a pipeline of products derived from human placenta, a non-controversial and non-embryonic adult stem cell source. These cells possess immunomodulatory properties, protecting the recipient from immunological reactions and requiring no histocompatibility matching.

Once produced, these PLX (PLacental eXpanded) cell products are stored and ready-to-use for the treatment of a variety of severe diseases where current therapies are unavailable or inadequate. Although Pluristem is currently focusing on a few specific but significant products and diseases, the potential range of applications is far greater.

PLX-PAD, Pluristem’s first product, targets an annual $4 billion market, and is intended to treat patients suffering from the critical stage of peripheral artery disease (PAD), where blood supply is restricted to organs or extremities.

PLX-BMT, Pluristem’s second product, targets an annual $2 billion market, and is intended to resolve the global shortfall of matched hematopoietic (blood forming) stem cells for bone marrow transplantation. (Approximately 60% of leukemia patients are unable to find suitable bone marrow donors.)

PLX-STROKE targets an annual $4 billion market, and shows potential to become a new treatment for the functional recovery from an ischemic stroke. This is the most common kind of stroke, and is caused by an interruption in the flow of blood to the brain (as from a clot blocking a blood vessel).

In addition, Pluristem already has animal data suggesting its PLX cells are of value in meeting an unmet need in the treatment of other disorders such as Multiple Sclerosis )MS) and Crohn’s Disease. Moreover, the company believes its PLX cells are also potentially useful for such things as organ transplantation, orthopedic injuries, and the prevention of radiation sickness.

For more information visit www.Pluristem.com

Cumulus Media Inc. (CMLS) Confirms Exclusive Merger Negotiations With Citadel Broadcasting Corporation

Fuwei Films (FFHL) Announces Results of US Antidumping Review

Dataram (DRAM) Successfully Executing Channel Strategy

Feb. 18, 2011 (Business Wire) — Dataram Corporation (NASDAQ: DRAM), a worldwide leader in the manufacture of high-quality computer memory, storage products, software and services, today reported solid results with its channel-centric partner strategy. Dataram’s worldwide partner programs have demonstrated strong momentum during its current fiscal year, with growth exceeding overall corporate objectives.

Channel program revenue growth in North America is tracking to a 40% increase over the last fiscal year. EMEA partners are growing at a rate similar to North America, with key partners in Switzerland, Germany and Belgium exhibiting exceptional growth. One particular VAR in Belgium cited their Dataram relationship as a critical factor in securing a large new client, specifically by using the cost savings advantage of Dataram memory to provide a clear financial advantage.

“Partners have allowed us to extend our sales operations into geographies where we do not have Dataram offices or staff,” said Phil Marino, VP of Worldwide Sales at Dataram. “These areas include Israel, Saudi Arabia, Greece, Russia, Belgium, Switzerland, Ireland and South Africa. Partners have also allowed us to further develop territories where we have Dataram offices including UK, France and Germany.”

Gavin Tobin, Managing Director of Ethos Technology Ltd Ireland said, “Essentially we have found Dataram 100% flawless since we started using their products in our own brand servers which gives us great confidence offering the RAM to our customers for 3^rd party servers.”

The Premier Partner Program introduced in December 2009 focused on key partners who joined Dataram to support their new go-to-market strategy, organized around direct sales for strategic demand generation, while leveraging key partners to extend Dataram’s sales reach. Today, there are eight signed Premier Reseller Partners representing full geographic coverage across North America. Dataram and partners work closely to reduce their customers’ total cost of ownership by providing computing solutions that deliver superior price performance. Dataram’s focus on the growth of the Premier Channel will continue and revenue is expected to accelerate for the foreseeable future.

Dataram reports that Premier Partnerships have yielded material new customer relationships at marquis accounts and enables them to rapidly deploy campaigns targeted to specific market segments. Dataram provides the Premier Partners with programs to support their growth, including: market development funds, volume incentive rebates, and other best-in-class marketing services.

John Murphy, Executive VP, ASG said, “Dataram is a trusted partner to ASG. The value and support they bring to ASG has been a contributing factor to our growth.”

Additional information about Dataram’s Partner Programs, including how to become one of the company’s strategic VAR/reseller partners, is available at www.dataram.com, via email at partner@dataram.com or by phone at 1-609-799-0071.

About Dataram

Founded in 1967, Dataram is a worldwide leader in the manufacture of high-quality computer memory, storage and software products. Our products and services deliver IT infrastructure optimization, dramatically increase application performance and deliver substantial cost savings. Dataram solutions are deployed in 70 Fortune 100 companies and in mission-critical government and defense applications around the world. For more information about Dataram, visit www.dataram.com.

Follow us on Facebook, YouTube, Twitter and LinkedIn®

All names are trademarks or registered trademarks of their respective owners.

Dataram Contact:

Lisa Silva

Dataram Marketing

609-240-7118

lsilva@dataram.com

Essex Rental Corp. (ESSX) Provides Update on Coast Crane New Equipment Distribution

Feb. 18, 2011 (Business Wire) — Essex Rental Corp. (Nasdaq: ESSX; ESSXW; ESSXU) (“Essex”) today announced that its wholly owned subsidiary, Coast Crane Company (“Coast Crane”), has agreed to continue to serve as a new equipment dealer for certain Manitowoc products, consisting of Potain tower cranes, including the self-erecting and city hammerhead cranes, in the western US, Alaska, Hawaii and Guam.

Coast Crane will no longer serve as a distributor of new Manitowoc and Grove branded crawler and telescopic cranes, but will remain a National Key Account for all the Manitowoc Crane Group products which will allow Coast Crane to continue purchasing all new equipment for its rental fleet and parts directly from the manufacturer. This structure is similar to the successful relationship that has existed between Essex Crane and the Manitowoc Crane Group for more than fifteen years.

Besides the Potain tower crane lines, Coast Crane will continue to act as a new equipment dealer for several other manufacturers, including Tadano, Mantis, Little Giant, Manitex, Lull and other lines currently represented.

Ron Schad, President and CEO of Essex Rental Corp., stated, “We are pleased to continue representing certain Manitowoc products, and expect to add additional manufacturers’ product lines and territories in the near-term based on discussions that we have had to date. We consider our three core competencies to be new and used equipment distribution, a broad national offering of rental equipment, and service and parts support, and plan on aggressively building these primary business lines.”

Mr. Schad continued, “Thus far, we are pleased with the Coast Crane acquisition. We recently completed a comprehensive appraisal of Coast Crane’s assets and they were valued consistent with our purchase price. Further, the acquisition has broadened our business prospects and we are excited by the many growth opportunities presenting themselves, as well as with Coast Crane’s exceptionally dedicated and knowledgeable employees. These growth opportunities combined with improving asset utilization across our entire rental fleet will allow us to generate attractive returns for our shareholders.”

About Essex Rental Corp.

Essex, through its subsidiaries, Essex Crane Rental Corp. and Coast Crane Company, is one of North America’s largest providers of mobile cranes (including lattice-boom crawler cranes, truck cranes and rough terrain cranes), self-erecting cranes, stationary tower cranes, elevators and hoists, and other lifting equipment used in a wide array of construction projects. In addition, the Company provides product support including installation, maintenance, repair, and parts and services for equipment provided and other equipment used by its construction industry customers. With a fleet of over 1,000 cranes and other construction equipment and unparalleled customer service and support, Essex supplies a wide variety of innovative lifting solutions for construction projects related to power generation, petro-chemical, refineries, water treatment and purification, bridges, highways, hospitals, shipbuilding, offshore oil fabrication and industrial plants, and commercial and residential construction.

About Coast Crane Company

Founded in 1970, Coast Crane Company has grown to become the market leader for innovative lifting solutions throughout Western North America, Alaska, Hawaii, Guam and the South Pacific. The Company provides both used and new equipment including rough terrain cranes, boom trucks, tower cranes, and other lifting equipment. Products are rented and sold through a regional network including 13 branch locations and covering over 3,000 customer accounts. Coast Crane enjoys strong working partnerships with the leading crane and lifting manufacturers in the U.S. and has a dedicated and unparalleled customer service and support team.

Some of the statements in this press release and other written and oral statements made from time to time by Essex, Coast and their respective representatives are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding the intent and belief or current expectations of Essex, Coast and their respective management teams and may be identified by the use of words like “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, the negative of these terms or other comparable terminology. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Important factors that could cause actual results to differ materially from Essex’s or Coast’s expectations include, without limitation, the continued ability of Essex and Coast to successfully execute their respective business plans, the possibility of a change in demand for the products and services that Essex provides (through its subsidiary, Essex Crane) and that Coast provides, the failure to obtain Bankruptcy Court approval of the Coast acquisition, intense competition which may require us to lower prices or offer more favorable terms of sale, our reliance on third party suppliers, our indebtedness which could limit our operational and financial flexibility, global economic factors including interest rates, general economic conditions, geopolitical events and regulatory changes, our dependence on our management team and key personnel, as well as other relevant risks detailed in our Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission and available on our website, www.essexcrane.com. The factors listed here are not exhaustive. Many of these uncertainties and risks are difficult to predict and beyond management’s control. Forward-looking statements are not guarantees of future performance, results or events. Essex assumes no obligation to update or supplement forward-looking information in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results or financial conditions, or otherwise.

Essex Rental Corp.

Martin Kroll, 847-215-6502

Chief Financial Officer

mkroll@essexcrane.com

or

INVESTOR RELATIONS:

The Equity Group Inc.

Melissa Dixon, 212-836-9613

Senior Account Executive

mdixon@equityny.com

or

Devin Sullivan, 212-836-9608

Senior Vice President

dsullivan@equityny.com

Cheniere (CQP) Signs MOU With Endesa and Enel Trade for Bi-Directional Processing Capacity

Pioneer Drilling (PDC) Reports Fourth Quarter 2010 Results

Monotype Imaging (TYPE) Announces Fourth Quarter and Full Year 2010 Results

Feb. 17, 2011 (Business Wire) — Monotype Imaging Holdings Inc. (Nasdaq: TYPE), a leading global provider of text imaging solutions, today announced financial results for the fourth quarter and full year ended Dec. 31, 2010.

Fourth quarter and full year 2010 highlights:

• Fourth quarter revenue was $29.4 million, a 17 percent increase year-over-year. Full year 2010 revenue was $106.7 million, an increase of 13 percent year-over-year.
• Operating income for the fourth quarter increased 45 percent to $10.2 million. Full year 2010 operating income was $33.1 million, an increase of 25 percent over the prior year.
• Non-GAAP net adjusted EBITDA for the fourth quarter was $13.8 million, or 47 percent of revenue. Full year 2010 non-GAAP net adjusted EBITDA was $47.8 million, or 45 percent of revenue.
• Cash flow from operations for the full year ended Dec. 31, 2010, was $43.7 million, a 56 percent increase over the prior year period.

“2010 was a year of recovery and progress for Monotype Imaging, capped by a record fourth-quarter performance,” said Doug Shaw, president and chief executive officer. “Looking forward to 2011, we are well positioned to capitalize on our expanded product portfolio and deliver increased value to our customers.”

Scott Landers, senior vice president and chief financial officer, said, “We’ve demonstrated once again the ability to drive double-digit organic growth. We’ve also held true to our business model, resulting in expanded margins as our top line growth accelerated. We exited 2010 in a strong financial position with cash balances in excess of $40 million and net debt of $23 million.”

Fourth quarter operating results

Revenue for the fourth quarter of 2010 was $29.4 million, up 17 percent compared to $25.1 million in the fourth quarter of 2009. OEM revenue for the quarter was $22.5 million, an increase of 22 percent year-over-year. Creative Professional revenue for the quarter was $6.9 million, increasing four percent from the fourth quarter of 2009.

Net income for the fourth quarter of 2010 was $6.1 million, compared to $4.0 million in the prior year period. Earnings per diluted share for the fourth quarter of 2010 were $0.17, compared to $0.11 in the fourth quarter of 2009.

In the fourth quarter of 2010, non-GAAP net adjusted EBITDA was $13.8 million or 47 percent of revenue, compared to $10.6 million or 42 percent in the fourth quarter of 2009.

Full year 2010 operating results

Revenue for the full year 2010 was $106.7 million, an increase of 13 percent compared to $94.0 million in the full year 2009. OEM revenues were $80.0 million, increasing 16 percent year-over-year. Creative Professional revenues were $26.7 million, an increase of six percent year-over-year.

Net income for the full year 2010 was $18.4 million, compared to net income of $13.4 million for the prior year. Earnings per diluted share for the full year 2010 were $0.51 compared to earnings per diluted share of $0.38 for the full year 2009.

For the full year 2010, non-GAAP net adjusted EBITDA was $47.8 million or 45 percent, compared to non-GAAP net adjusted EBITDA of $41.0 million or 44 percent for the prior year.

A reconciliation of GAAP operating income to non-GAAP net adjusted EBITDA for the three and 12 months ended Dec. 31, 2010 and 2009 is provided in the financial tables that accompany this release.

Cash, cash flow and debt balances

Monotype Imaging had cash and cash equivalents of $42.8 million as of Dec. 31, 2010, an increase of $8.2 million from $34.6 million at the end of the prior year. Monotype Imaging generated $8.0 million of cash from operations in the fourth quarter of 2010 and $43.7 million on a full year basis.

The company’s outstanding debt was $65.9 million as of Dec. 31, 2010, a decrease from $78.5 million as of Sept. 30, 2010 and $91.4 million at the end of the prior year. The company was in compliance with all debt covenants at year end.

Net debt, defined as outstanding debt less cash and cash equivalents, was $23.1 million as of Dec. 31, 2010, a decrease of $33.7 million from the prior year end.

Introduction of additional Non-GAAP financial measures

Beginning in the first quarter of 2011, Monotype Imaging will add certain non-GAAP financial measures to its financial reporting, including non-GAAP net income and non-GAAP earnings per diluted share. These non-GAAP measures will exclude the amortization of intangible assets and stock-based compensation expense, net of taxes. Further information is provided in the non-GAAP financial measures section of this press release.

Financial outlook

For the first quarter of 2011, Monotype Imaging expects revenue in the range of $28.5 million to $30.0 million. The company expects first quarter 2011 non-GAAP net adjusted EBITDA in the range of $12.3 million to $13.3 million, GAAP earnings per diluted share in the range of $0.12 to $0.14 and non-GAAP earnings per diluted share in the range of $0.18 to $0.20.

For full year 2011, Monotype Imaging expects revenue in the range of $119.0 million to $123.0 million. The company expects full year 2011 non-GAAP net adjusted EBITDA in the range of $52.0 million to $55.0 million and GAAP earnings per diluted share in the range of $0.55 to $0.60 and non-GAAP earnings per diluted share in the range of $0.80 to $0.85.

Conference call details

Monotype Imaging will host a conference call on Thursday, Feb. 17, 2011 at 8:30 a.m. EST to discuss the company’s fourth quarter and full year 2010 results and business outlook for 2011. Individuals who are interested in listening to the audio webcast should log on to the “Investor Relations” portion of the “About Us” section of Monotype Imaging’s website at www.monotypeimaging.com. The live call can also be accessed by dialing (877) 941-2927 (domestic) or (480) 629-9724 (international) using passcode 4401292. If individuals are unable to listen to the live call, the audio webcast will be archived in the “Investor Relations” portion of the company’s website for one year.

Non-GAAP financial measures

This press release contains non-GAAP financial measures under the rules of the U.S. Securities and Exchange Commission. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by generally accepted accounting principles. Non-GAAP financial measures are used internally to manage the business, such as in establishing an annual operating budget and in reporting to lenders. Non-GAAP financial measures are used by Monotype Imaging management in its operating and financial decision-making because management believes these measures reflect ongoing business in a manner that allows meaningful period-to-period comparisons. Accordingly, Monotype Imaging believes it is useful for investors and others to review both GAAP and non-GAAP measures in order to (a) understand and evaluate current operating performance and future prospects in the same manner as management does and (b) compare in a consistent manner the company’s current financial results with past financial results. The primary limitations associated with the use of non-GAAP financial measures are that these measures may not be directly comparable to the amounts reported by other companies and they do not include all items of income and expense that affect operations. Monotype Imaging management compensates for these limitations by considering the company’s financial results and outlook as determined in accordance with GAAP and by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached to this press release.

Forward-looking statements

This press release may contain forward-looking statements including those related to future revenues and operating results, the growth of the company’s OEM business and Creative Professional business, the execution of the company’s growth strategy and anticipated business momentum that involve risks and uncertainties that could cause the company’s actual results to differ materially. Factors that might cause or contribute to such differences include, but are not limited to: risks associated with changes in the economic climate, including decreased demand for fonts or products that incorporate the company’s text imaging solutions; risks associated with changes in the financial markets, including the availability of credit; risks associated with increased competition, which may result in the company losing customers or force it to reduce prices; risks associated with the development and market acceptance of new products or product features; risks associated with the company’s ability to adapt its products to new markets and to anticipate and quickly respond to evolving technologies and customer requirements; risks associated with the company’s recent acquisition; and risks associated with the ownership and enforcement of the company’s intellectual property. Additional disclosure regarding these and other risks faced by the company is available in the company’s public filings with the Securities and Exchange Commission, including the risk factors included in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2009 and subsequent filings. The forward-looking financial information set forth in this press release reflects estimates based on information available at this time. These amounts could differ from actual reported amounts stated in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2010. While Monotype Imaging may elect to update forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if an estimate changes.

About Monotype Imaging

Monotype Imaging combines technology with design to help the world communicate. Based in Woburn, Mass. with offices in the U.S., Europe and Asia, Monotype Imaging brings text imaging and graphical user interface capabilities to consumer electronics devices such as laser printers, copiers, mobile phones, navigation devices, digital cameras, e-book readers, digital televisions, set-top boxes and consumer appliances. The company also provides printer drivers and color imaging solutions to printer manufacturers and OEMs (original equipment manufacturers). Monotype Imaging technologies are combined with access to more than 14,000 typefaces from the Monotype^®, Linotype^® and ITC^® typeface libraries – home to some of the world’s most widely used designs, including the Times New Roman^®, Helvetica^® and ITC Franklin Gothic^™ typefaces. Fonts are licensed to creative, business and Web professionals through e-commerce portals, direct and indirect sales and custom design services. Monotype Imaging offers industry-standard font solutions that support all of the world’s major languages. Information about Monotype Imaging can be found at www.monotypeimaging.com.

Monotype is a trademark of Monotype Imaging Inc. registered in the U.S. Patent and Trademark Office and may be registered in certain jurisdictions. Times New Roman is a trademark of The Monotype Corp. registered in the U.S. Patent and Trademark Office and may be registered in certain other jurisdictions. Linotype is a trademark of Linotype GmbH registered in the U.S. Patent and Trademark Office and may be registered in certain jurisdictions. Helvetica is a trademark of Linotype Corp. registered in the U.S. Patent and Trademark Office and may be registered in certain jurisdictions in the name of Linotype Corp. or its licensee Linotype GmbH. ITC is a trademark of International Typeface Corp. registered in the U.S. Patent and Trademark Office and may be registered in certain jurisdictions. ITC Franklin Gothic is a trademark of International Typeface Corp. and may be registered in certain jurisdictions. All other trademarks are the property of their respective owners. © 2011 Monotype Imaging Holdings Inc. All rights reserved.

Assumes 35% effective tax rate.

Assumes 35% effective tax rate.

ICR

Staci Mortenson, 781-970-6120

ir@monotypeimaging.com

Hardinge Inc. (HDNG) Announces Fourth Quarter Net Income of $1.9 Million

3D Systems (TDSC) Earns 40 Cents Per Share on Record Fourth Quarter Revenue

ROCK HILL, S.C., Feb. 17, 2011 (GLOBE NEWSWIRE) — 3D Systems Corporation (Nasdaq:TDSC) announced today that it earned 40 cents per share, fully diluted, for the fourth quarter of 2010 on a 42% revenue increase and a 400 basis point gross profit margin expansion compared to the fourth quarter of 2009. The company’s quarterly and annual earnings per share benefitted by 5 cents per share from releasing a portion of its valuation allowance on deferred tax assets.

The company earned 83 cents per share, fully diluted, for the full year 2010 and generated $31.8 million of cash from operations. After using $20.8 million to fund strategic investing activities, the company ended 2010 with $37.3 million of available cash compared to $24.9 million at December 31, 2009.

“Our record fourth quarter and full year results validate our long term operating model,” said Abe Reichental, 3D Systems’ President and Chief Executive Officer.

Pluristem Therapeutics, Inc. (PSTI) Moves Ahead with PLX-PAD Clinical Trials

Pluristem, a leading developer of placenta-based cell therapies for treating local and systemic inflammatory diseases, feels that positive feedback received from both the FDA (Food and Drug Administration) and the EMA (European Medical Agencies) regarding its PLX-PAD product for treating PAD (Peripheral Artery Disease), a chronic disease that progressively restricts blood flow in the limbs, clears the way for further clinical studies with its PLX-PAD cells. The company is now on track to proceed to a Phase II/III trial for CLI (Critical Limb Ischemia) and a Phase II trial for IC (Intermittent Claudication).

The company recently announced the successful completion of a parallel scientific advisory process involving both the U.S. Food and Drug Administration and the European Medical Agencies, in which the FDA and EMA both acknowledged Pluristem’s proposed clinical development plan for PLX-PAD. The goal is to develop an advanced cell therapy product that could help millions of PAD patients.

Pluristem Chairman and CEO, Zami Aberman, commented on the success. “The completion of two Phase-I CLI clinical studies, performed in parallel in Germany and the U.S., placed Pluristem in a unique position to discuss with the regulatory agencies an approach that should allow a single clinical study protocol to be accepted by both agencies. What is particularly exciting about this development is that it places us – for the first time – on-track for a potentially preventative treatment for PAD in addition to treating amputation-destined cases.”

Edwin Horwitz, MD, PhD, President of the International Society for Cell Therapy, and head of Pluristem’s scientific advisory board, added: “PLX-PAD has shown an early read-out of efficacy throughout its clinical development and I am pleased that PLX-PAD has made the necessary progress from a regulatory perspective, to move forward with advanced trials. I am excited that the PLX-PAD clinical trials will be conducted in the EU and the U.S. under the same clinical protocol, bringing the therapy closer to market and to those CLI patients in need of improved therapies.”

Pluristem’s patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. The cells are grown using the company’s proprietary 3D micro-environmental technology, and offer an off-the-shelf solution that requires no tissue matching or immune-suppression treatment prior to administration. PLX-PAD is set to target a sub-population of 20 million patients suffering from Peripheral Artery Disease.

For more information visit www.Pluristem.com

China GengSheng Minerals (CHGS) Awarded $10.5 Million Fracture Proppant Export Contract

GONGYI, China, Feb. 16, 2011 /PRNewswire-Asia-FirstCall/ — China GengSheng Minerals, Inc. (“GengSheng“) (AMEX:CHGS), a leading China-based high-tech industrial materials manufacturer producing heat resistant, energy efficient materials for a variety of industrial applications, today announced that it has been awarded $10.5 million a follow-on contract for its fracture proppants from a China-based distributor specializing in sales to overseas oil and gas companies. GengSheng will begin shipments to this customer in February 2011 and expects to supply approximately 27,000 tons of proppant products over a six-month period.

“During 2010, we achieved tremendous growth in our fracture proppant business, driven by robust demand from both domestic and international customers. Throughout the year, we worked to develop strong relationships with our customers and key distributors, and it is clear that these efforts are bearing fruit. We are pleased that this distributor has recognized the quality of our products and high level of customer service we provide by awarding us this significant follow-on order,” said Mr. Shunqing Zhang, China GengSheng’s Chairman and Chief Executive Officer. “We entered 2011 with our proppant manufacturing operations near full capacity. We expect drilling activity to remain high throughout the year, driving continued strong demand for proppant materials. In an effort to capture this anticipated demand, we are currently exploring opportunities to expand our fracture proppant manufacturing capacity later in the year.”

GengSheng commercially launched its fracture proppant products in the second quarter of 2007, and reported full-year 2009 revenue from this product segment of $8 million, representing a 3-year CAGR of 323%. Fracture proppant sales in the third quarter of 2010 were a record $5 million. In order to meet the growing demand for its fracture proppant products, GengSheng signed a 3-year operating facility lease in the fourth quarter of 2010. This facility increased the Company’s fracture proppant manufacturing capacity to 75,000 metric tons per year.

About China GengSheng Minerals, Inc.

China GengSheng Minerals, Inc. (“GengSheng”) develops, manufactures and markets a broad range of high-tech industrial material products, including monolithic refractories, industrial ceramics and fracture proppants. A market leader offering customized solutions, GengSheng sells its products primarily to the iron-and-steel industry as heat-resistant components for steel-making furnaces, industrial kilns and other high-temperature vessels to guarantee and improve the productivity of those expensive pieces of equipment while reducing their consumption of energy. Founded in 1986 and based in China’s Henan province, GengSheng currently has over 200 customers in the iron, steel, oil, glass, cement, aluminum and chemical businesses located in China and other countries. GengSheng conducts business through GengSheng International Corporation, a British Virgin Islands company, and its Chinese subsidiaries, which are Henan GengSheng Refractories Co., Ltd., Zhengzhou Duesail Fracture Proppant Co., Ltd., Henan GengSheng Micronized Powder Materials Co., Ltd, Guizhou SouthEast Prefecture Co., Ltd., GengSheng New Materials Co., Ltd, and Henan GengSheng High Temperature Materials Co., Ltd.

For more information about GengSheng, please visit http://www.gengsheng.com.

To be added to GengSheng’s email distribution for future press releases, please send your request to gengsheng@tpg-ir.com.

Note Regarding Forward-Looking Statements

This press release contains statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “will likely, ” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such forward-looking statements are only predictions and are not guarantees of future performance. Investors are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties, certain assumptions and factors relating to the operations and business environments of China GengSheng Minerals, Inc. and its subsidiaries that my cause the actual results of the companies to be materially different from any future results expressed or implied in such forward-looking statements. Although China GengSheng Minerals, Inc. believes that the expectations and assumptions reflected in the forward-looking statements are reasonable based on information currently available to its management, China GengSheng Minerals, Inc. cannot guarantee future results or events. China GengSheng Minerals, Inc. expressly disclaims a duty to update any of the forward-looking statement.

Hyperdynamics (HDY) Announces Addition to its Management Staff

HOUSTON, Feb. 16, 2011 /PRNewswire/ — Hyperdynamics Corporation (NYSE Amex: HDY) announced today that Andrei Orlov has joined the company as Vice President for Business Development based in London, England.

Orlov most recently was a Regional Director of Foster Wheeler, a global engineering and construction firm, and prior to that, Vice President for Business Development in the former Soviet Union with SNC Lavalin, Canada’s largest engineering firm. He has more than 15 years of international project and business development experience for the oil and gas industry in Europe and the former Soviet Union.

“With the addition of Andrei Orlov to our team, we are continuing to build the solid management and operational capabilities to enable Hyperdynamics to grow in the future,” said Ray Leonard, President and Chief Executive Officer. “Andrei’s years of experience in the field of international mergers and acquisitions will be an invaluable addition to the management team of Hyperdynamics. He will be responsible for the business development function of the company and will work closely with the Houston and Guinea offices in our farm-out and expansion efforts.”

About Hyperdynamics

Hyperdynamics is an emerging independent oil and gas exploration and production company that is exploring for oil and gas offshore the Republic of Guinea in West Africa.  To find out more, visit our website at www.hyperdynamics.com.

Forward Looking Statements

This news release and the Company’s website referenced in this news release contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding Hyperdynamics Corporation’s future plans and expected performance that are based on assumptions the Company believes to be reasonable. Statements preceded by, followed by or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans”, “may increase”, “may result”, “will result”, “may fluctuate” and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. A number of risks and uncertainties could cause actual results to differ materially from these statements, including without limitation, funding and exploration efforts, fluctuations in oil and gas prices and other risk factors described from time to time in the Company’s reports filed with the SEC, including the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2010. The Company undertakes no obligation to publicly update these forward looking statements to reflect events or circumstances that occur after the issuance of this news release or to reflect any change in the Company’s expectations with respect to these forward looking statements.

HDY-IR

Syneron (ELOS) Reports Fourth Quarter 2010 Results

YOKNEAM, ISRAEL — (Marketwire) — 02/16/11 — Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced fourth quarter 2010 financial results for the three month period ended December 31, 2010. Fourth quarter 2010 financial results are for Syneron and Candela as a combined company. The fourth quarter 2009 year-over-year comparative financial results referred to below are pro-forma financial results assuming the merger with Candela Corporation had occurred on January 1, 2009.

Fourth Quarter 2010 Highlights Include:

--  Revenue of $53.5 million, up 14.7% year-over-year
--  International revenue of $35.3 million, up 20% year-over-year
--  North America revenue of $18.2 million, up 5.7% year-over-year
--  Non-GAAP gross margin of 54.4%, up from 50.0% in the prior year and
    52.3% in Q3 2010
--  Non-GAAP net income from continuing operations before non-controlling
    interest of $3.4 million, or 6.3% of revenue compared to a net loss of
    $4.1 million in the prior year and $1.5 million in Q3 2010
--  Non-GAAP earnings per share (basic and diluted) of $0.10, compared to a
    loss per share of $0.12 in the prior year and $0.04 in Q3 2010
--  Net cash and investments portfolio of $215.2 million at
    December 31, 2010
--  Global launch of CO2RE and elure

Lou Scafuri, Chief Executive Officer of Syneron, commented, “The strength of our fourth quarter results clearly demonstrates the benefits of the Syneron and Candela merger. The combined businesses have an unmatched product portfolio and global sales network, which are supported by strong clinical data and customer relationships. We have successfully executed on the integration plan and leveraged these factors to drive continued revenue growth while also focusing on driving operational efficiencies and investing in new growth opportunities.

“We made significant progress on the new product front during the quarter, including global launches of our CO2RE Fractional CO2 Resurfacing System and elure Advanced Skin Lightening Technology. In addition, we are on schedule to launch the ePrime Energy-Based Dermal Remodeling during the first quarter, followed by several additional anticipated new product launches throughout the year. We have received positive feedback on all of the recently launched products, including at the American Academy of Dermatology annual meeting earlier this month.

“As part of our growth strategy, during the quarter we acquired the Tända line of LED home-use products, giving us an immediate presence in the important aesthetic home-use market. Tända represents a synergistic growth opportunity with our other direct to consumer initiatives and we expect this to become an increasingly important part of our business as we launch these new products.”

Revenue: Fourth quarter 2010 revenue was $53.5 million, an increase of 14.7% compared to $46.6 million in the fourth quarter 2009. International revenue was $35.3 million, an increase of 20% compared to $29.5 million in the fourth quarter 2009. Fourth quarter 2010 revenue in North America was $18.2 million, an increase of 5.7% compared to $17.2 million in the fourth quarter 2009.

Non-GAAP Financial Highlights for the Fourth Quarter Ended December 31, 2010:

Gross Margin: Fourth quarter 2010 gross margin was 54.4%, compared to 50.0% in the fourth quarter 2009 and 52.3% in the third quarter 2010.

Operating Income (loss): Fourth quarter 2010 operating income was $4.0 million, compared to an operating loss of $5.8 million in the fourth quarter 2009 and an operating loss of $0.5 million in the third quarter 2010. Fourth quarter 2010 operating income represented 7.5% of revenue in the quarter, compared to an operating loss of 12.4% of revenue in the fourth quarter 2009 and 1.1% of revenue in the third quarter 2010.

Net Income (loss): Fourth quarter 2010 income from continuing operations before non-controlling interest was $3.4 million, compared to a loss of $4.1 million in the fourth quarter 2009 and a loss of $1.5 million in the third quarter 2010.

Fourth quarter non-GAAP operating income and net income excludes one-time income and expenses as detailed in the Company’s financial tables, with the main item being a one-time income of $8.5 million related to the recognition of a deferred gain related to the Company’s merger with Candela Corporation.

Earnings Per Share: Fourth quarter 2010 earnings per share (basic and diluted) was $0.10, compared to a loss per share of $0.12 in the fourth quarter 2009 and a loss per share of $0.04 in the third quarter 2010.

GAAP Financial Highlights for the Fourth Quarter Ended December 31, 2010:

Gross Margin: Fourth quarter 2010 gross margin was 52.5%, compared to 49.0% in the fourth quarter 2009 and 50.8% in the third quarter 2010.

Operating Income (loss): Fourth quarter 2010 operating income was $8.0 million, compared to an operating loss of $8.6 million in the fourth quarter 2009 and an operating loss of $5.0 million in the third quarter 2010.

Net Income (loss) from continuing operations before non-controlling interest: Fourth quarter 2010 net income was $8.1 million, compared to a net loss of $6.2 million in the fourth quarter of 2009 and a loss of $5.3 million in the third quarter 2010.

Earnings Per Share: Fourth quarter 2010 earnings per share basic was $0.25 and diluted was $0.24, compared to a loss per share of $0.18 in the fourth quarter 2009 and a loss per share of $0.15 in the third quarter 2010.

Cash Position: As of December 31, 2010, net cash and cash equivalents, including short-term bank deposits and investments in marketable securities, were $215.2 million.

Asaf Alperovitz, Chief Financial Officer of Syneron, commented, “Beginning this quarter, we are breaking out our financial results between Professional Aesthetic Devices and Emerging Business Units in order to provide increased transparency into our results. We believe this segment reporting will allow investors to better gauge the growth and significant investments we are making as part of our overall growth strategy in our emerging technologies that are primarily targeted at the home-use consumer market. Products in the Emerging Business Units segment include eLure skin whitening, Tända LED systems, MEmyelos hair removal system, Light Instruments’ dental laser devices along with pipeline products that include our strategic home-use device partnership with Procter & Gamble and Fluorinex teeth whitening and fluorination. Segment reporting will also provide a view of the operating results for the traditional Syneron and Candela business, which we have labeled as Professional Aesthetic Devices, or PAD.”

Mr. Alperovitz added, “Our fourth quarter 2010 results in the PAD segment demonstrate a significant improvement in margins that we believe is indicative of the potential leverage we can drive from the combined Syneron and Candela business. Additionally, for the full year 2010 the PAD segment was operationally profitable on a non-GAAP basis. In 2011, we expect further margin improvements for our PAD segment as our mix shifts in favor of higher gross margin products and consumables and we execute on our cross selling opportunities and additional efficiency initiatives that we see in the business.”

Unaudited Non-GAAP segment results for the three months ended December 31, 2010 and 2009 (in thousands):

                          For the three-months ended
                ----------------------------------------------
                 December                December
                    31,        % of         31,        % of        % of
                   2010      Revenues      2009      Revenues     Change
                ----------  ----------  ----------  ----------  ----------

Revenues

  Professional
   Aesthetic
   Devices      $   52,170        97.4% $   46,615        99.9%       11.9%
  Emerging
   Business
   Units             1,373         2.6%         60         0.1%     2188.3%
                ----------              ----------

Total revenues  $   53,543       100.0% $   46,675       100.0%       14.7%
                ==========              ==========

  Professional
   Aesthetic
   Devices      $    5,948        11.4% $   (3,692)       -7.9%     -261.1%
  Emerging
   Business
   Units            (1,926)     -140.3%     (2,097)    -3495.0%       -8.2%
                ----------              ----------

Total operating
 income (loss)  $    4,022         7.5% $   (5,789)      -12.4%     -169.5%
                ==========              ==========

Unaudited Non-GAAP segment results for the twelve months ended December 31, 2010 and 2009 (in thousands):

                          For the twelve-months ended
                ----------------------------------------------
                 December                December
                    31,        % of         31,        % of        % of
                   2010      Revenues      2009      Revenues     Change
                ----------  ----------  ----------  ----------  ----------

Revenues

  Professional
   Aesthetic
   Devices      $  185,951        97.9% $  171,473        98.3%        8.4%
  Emerging
   Business
   Units             3,927         2.1%      2,908         1.7%       35.0%
                ----------              ----------

Total revenues  $  189,878       100.0% $  174,381       100.0%        8.9%
                ==========              ==========

Operating
 income (loss)

  Professional
   Aesthetic
   Devices      $      302         0.2% $  (22,453)      -13.1%     -101.3%
  Emerging
   Business
   Units            (6,117)     -155.8%     (3,211)     -110.4%       90.5%
                ----------              ----------

Total operating
 loss           $   (5,815)       -3.1% $  (25,664)      -14.7%      -77.3%
                ==========              ==========

Unaudited GAAP segment results for the three months ended December 31, 2010 and 2009 (in thousands):

                          For the three-months ended
                ----------------------------------------------
                 December                December
                    31,        % of         31,        % of        % of
                   2010      Revenues      2009      Revenues     Change
                ----------  ----------  ----------  ----------  ----------

Revenues

 Professional
  Aesthetic
  Devices       $   52,083        97.4% $   46,528        99.9%       11.9%
 Emerging
  Business
  Units              1,373         2.6%         60         0.1%     2188.3%
                ----------              ----------

Total revenues  $   53,456       100.0% $   46,588       100.0%       14.7%
                ==========              ==========

Operating
 income (loss)

  Professional
   Aesthetic
   Devices      $    9,963        19.1% $   (6,502)      -14.0%     -253.2%
  Emerging
   Business
   Units            (1,926)     -140.3%     (2,097)    -3495.0%       -8.2%
                ----------              ----------

Total operating
 income (loss)  $    8,037        15.0% $   (8,599)      -18.5%     -193.5%
                ==========              ==========

Unaudited GAAP segment results for the twelve months ended December 31, 2010 and 2009 (in thousands):

                          For the twelve-months ended
                ----------------------------------------------
                 December                December
                    31,        % of         31,        % of        % of
                   2010      Revenues      2009      Revenues     Change
                ----------  ----------  ----------  ----------  ----------

Revenues

  Professional
   Aesthetic
   Devices      $  185,601        97.9% $  171,124        98.3%        8.5%
  Emerging
   Business
   Units             3,927         2.1%      2,908         1.7%       35.0%
                ----------              ----------

Total revenues  $  189,528       100.0% $  174,032       100.0%        8.9%
                ==========              ==========

Operating
 income (loss)

  Professional
   Aesthetic
   Devices      $  (27,285)      -14.7% $  (35,318)      -20.6%      -22.7%
  Emerging
   Business
   Units            (6,117)     -155.8%     (3,211)     -110.4%       90.5%
                ----------              ----------

Total operating
 loss           $  (33,402)      -17.6% $  (38,529)      -22.1%      -13.3%
                ==========              ==========

Use of Non-GAAP Measures

This press release provides financial measures for gross margin, net income (loss), net income ( loss) per basic and diluted share, which exclude one-time expenses relating to the mergers with Candela Corporation and Primeva Medical Inc, one-time income due to reversal of a deferred gain related to the merger with Candela Corporation, and an expense charge related to stock-based compensation and amortization and are therefore not calculated in accordance with generally accepted accounting principles (GAAP). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance because it reflects our operational results and enhances management’s and investors’ ability to evaluate the Company’s gross margin, net loss and net loss per basic and diluted share. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when evaluating the business internally and, therefore, felt it important to make these non-GAAP adjustments available to investors. A reconciliation of each GAAP to non-GAAP financial measure discussed in this press release is contained in the accompanying financial tables.

Conference call

Syneron management will host its fourth quarter 2010 earnings conference call today at 8:30 a.m. ET. Syneron will be broadcasting live via the Investor Relations section of its website, www.syneron.com. To access the call, enter the Syneron website, then click on the Investors Relations Overview and select “Q4 2010 Results Conference Call.”

Participants are encouraged to log on at least 15 minutes prior to the conference call in order to download the applicable audio software. The call can be heard live or with an on-line replay which will follow. Those interested in participating in the call and the question and answer session should dial 877-844-6886 in the U.S., and 970-315-0315 from overseas. The conference pass code is: 31269957.

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing “believes,” “anticipates,” “plans,” “expects,” “may,” “will,” “would,” “intends,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.’s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.’s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.’s views as of any date after the date of this document.

Syneron, the Syneron logo, eMatrix and elos are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. The elos (Electro-Optical Synergy) technology is a proprietary technology of Syneron Medical Ltd. All other names are the property of their respective owners.

                           Syneron Medical Ltd.
       Unaudited Condensed Consolidated Statements of Income (Loss)
                  (in thousands, except per share data)

                                      For the               For the
                                three-months ended    twelve-months ended
                                -------------------   -------------------
                                December   December   December   December
                                   31,        31,        31,        31,
                                  2010       2009       2010       2009
                                ---------  ---------  ---------  ---------

Revenue                         $  53,456  $  14,403  $ 189,528  $  54,726
Cost of sales                      25,395      4,239    101,099     18,903
                                ---------  ---------  ---------  ---------
Gross profit                       28,061     10,164     88,429     35,823
Operating expenses:
  Sales and marketing              14,310      7,869     63,429     34,156
  General and administrative        6,612      3,419     36,103     16,478
  Research and development          6,414      4,271     26,837     13,220
  Other income, net                (7,312)         -     (4,538)         -
  Legal settlement, net                 -          -          -     (3,975)
                                ---------  ---------  ---------  ---------
Total operating expenses           20,024     15,559    121,831     59,879
                                ---------  ---------  ---------  ---------
Income (loss) from operations       8,037     (5,395)   (33,402)   (24,056)
Other income:
  Financial Income, net               419        436        717      2,097
  Other income                        110        562         44        562
                                ---------  ---------  ---------  ---------
  Total other income                  529        998        761      2,659
                                ---------  ---------  ---------  ---------
Income (loss) from continuing
 operations before income taxes     8,566     (4,397)   (32,641)   (21,397)
(Benefit) expense from income
 taxes                                427        785     (5,110)     3,240
                                ---------  ---------  ---------  ---------
Income (loss) from continuing
 operations before
 non-controlling interest           8,139     (5,182)   (27,531)   (24,637)
Net loss attributable to
 non-controlling interest             244        837      1,799      1,050
Income from discontinued
 operations, net of income
 taxes                                  -          -        196          -
                                ---------  ---------  ---------  ---------
Net income (loss) attributable
 to Syneron shareholders        $   8,383  $  (4,345) $ (25,536) $ (23,587)
                                =========  =========  =========  =========

Income (loss) per share:

Basic
  Income (loss) from continuing
   operations before
   non-controlling interest     $    0.24  $   (0.19) $   (0.80) $   (0.90)
  Net loss attributable to
   non-controlling interest          0.01       0.03       0.05       0.04
  Income from discontinued
   operations                           -          -       0.01          -
                                ---------  ---------  ---------  ---------
  Net Income (loss)
   attributable to Syneron
   shareholders                 $    0.25  $   (0.16) $   (0.74) $   (0.86)
                                ---------  ---------  ---------  ---------
Diluted
  Income (loss) from continuing
   operations before
   non-controlling interest     $    0.23  $   (0.19) $   (0.80) $   (0.90)
  Net loss attributable to
   non-controlling interest           0.01       0.03       0.05       0.04
  Income from discontinued
   operations                           -          -       0.01          -
                                ---------  ---------  ---------  ---------
  Net Income (loss)
   attributable to Syneron
   shareholders                 $    0.24  $   (0.16) $   (0.74) $   (0.86)
                                ---------  ---------  ---------  ---------

Weighted average shares
 outstanding:
  Basic                            34,533     27,591     34,369     27,526
                                ---------  ---------  ---------  ---------
  Diluted                          34,998     27,591     34,369     27,526
                                ---------  ---------  ---------  ---------

                           Syneron Medical Ltd.
                  Condensed Consolidated Balance Sheets
                              (in thousands)

                                                     December    December
                                                        31,         31,
                                                       2010        2009
                                                    ----------- -----------
                                                    (unaudited)  (audited)
Assets

Current assets:
  Cash and cash equivalents                         $    63,821 $    24,372
  Short-term bank deposits                                1,590       1,000
  Available-for-sale marketable securities              114,799     169,309
  Accounts receivable, net                               42,440      13,758
  Other current assets                                   13,868       2,753
  Inventories, net                                       22,720       8,592
                                                    ----------- -----------

Total current assets                                    259,238     219,784
                                                    ----------- -----------

Non-current assets:
  Severance pay fund                                        334         246
  Long-term deposits and others                           2,346         221
  Long-term available-for-sale marketable
   securities                                            37,721      11,449
  Investments in affiliated companies                     9,369       1,050
  Property and equipment, net                             4,029       2,885
  Goodwill and Intangible assets, net                    56,818      34,632
  Deferred taxes                                          6,854           -
                                                    ----------- -----------

Total non-current assets                                117,471      50,483
                                                    ----------- -----------

Total assets                                        $   376,709 $   270,267
                                                    =========== ===========

Liabilities and Stockholders' Equity

Current liabilities:
  Bank indebtedness                                 $     2,737 $         -
  Accounts payable                                       16,644       3,735
  Other accounts payable and accrued expenses            55,056      30,153
                                                    ----------- -----------

Total current liabilities                                74,437      33,888
                                                    ----------- -----------

Non-current liabilities:
  Contingent consideration                               11,365       7,331
  Deferred Revenues                                       4,528         902
  Warranty Accruals                                       1,074         558
  Accrued severance pay                                     554         330
  Deferred taxes                                          6,215           -
                                                    ----------- -----------

Total non-current liabilities                            23,736       9,121
                                                    ----------- -----------

Stockholders' equity:                                   278,536     227,258
                                                    ----------- -----------

Total liabilities and stockholders' equity          $   376,709 $   270,267
                                                    =========== ===========

                           Syneron Medical Ltd.
        Unaudited Condensed Consolidated Statements of Cash Flows
                              (in thousands)

                                                           For the
                                                     twelve months ended:
                                                    ----------------------
                                                     December    December
                                                        31,         31,
                                                       2010        2009
                                                    ----------  ----------
Cash flows from operating activities:
  Net loss before non-controlling interest          $  (27,335) $  (24,637)
    Adjustments to reconcile net loss to net cash
     used by operating activities:
    Share-based compensation expense                     3,196       4,264
    Depreciation and amortization                        9,186       1,927
    Impairments of available-for-sale marketable
     securities and other intangible assets              1,378         173
    Impairment of investment in an affiliated
     company                                               850           -
    Realized loss, changes in accrued interest, and
     amortization of premium on marketable
     securities                                            970       1,578
    Deferred gain related to acquisition of
     Subsidiary and revaluation of contingent
     liability                                          (6,900)          -
    Gain on  investments in affiliated companies as
     a result of a business combination                      -        (562)
    Changes in operating assets and liabilities
      Accounts receivable                                  450      18,879
      Inventories                                       13,180       4,320
      Other current assets                              (4,506)         64
      Deferred taxes                                     7,105       1,549
      Accrued severance pay, net                           136          (9)
      Accounts payable                                   4,201      (5,039)
      Deferred revenue                                  (3,885)     (3,608)
      Accrued warranty costs                               315          (4)
      Other accrued liabilities                         (4,732)        160
                                                    ----------  ----------

Net cash used by operating activities                   (6,391)       (945)
                                                    ----------  ----------

Cash flows from investing activities:
    Purchases of property and equipment                   (887)       (487)
    Maturities of held-to-maturity marketable
     securities                                            460           -
    Proceeds from the sale of available-for-sale
     marketable securities                             210,228     256,735
    Purchase of available-for-sale marketable
     securities                                       (182,961)   (294,345)
    Cash paid for investments in affiliated
     companies                                          (5,000)       (750)
    Net cash (paid in) received from acquisition of
     subsidiary                                         21,602      (7,729)
    Other investing activities                            (360)     (1,022)
                                                    ----------  ----------

Net cash provided by (used by) investing activities     43,082     (47,598)
                                                    ----------  ----------

Cash flows from financing activities:
    Proceeds from exercise of stock options              1,932         549
                                                    ----------  ----------

Net cash provided by financing activities                1,932         549
                                                    ----------  ----------

Effect of exchange rates on cash and cash
 equivalents                                               826           -
                                                    ----------  ----------

Net increase (decrease) in cash and cash
 equivalents                                            39,449     (47,994)

Cash and cash equivalents at beginning of period        24,372      72,366
                                                    ----------  ----------

Cash and cash equivalents at end of period          $   63,821  $   24,372
                                                    ==========  ==========

                           Syneron Medical Ltd.
         Unaudited Non-GAAP Financial Measures and Reconciliation
                  (in thousands, except per share data)

                                     For the               For the
                                three-months ended    twelve-months ended
                                --------------------  --------------------
                                December   December   December   December
                                   31,        31,        31,        31,
                                  2010       2009       2010       2009
                                ---------  ---------  ---------  ---------

GAAP operating income (loss)    $   8,037  $  (5,395) $ (33,402) $ (24,056)

  Stock-based compensation            692        837      3,196      4,264
  Amortization of acquired
   intangible assets                2,019         68      6,668        272
  Merger, restructuring and
   other non-recurring items,
   net                             (6,726)         -     17,723          -
                                ---------  ---------  ---------  ---------

Non-GAAP operating income
 (loss)                         $   4,022  $  (4,490) $  (5,815) $ (19,520)
                                =========  =========  =========  =========

GAAP income (loss) from
 continuing operations
 before non-controlling
 interest                       $   8,139  $  (5,182) $ (27,531) $ (24,637)

  Stock-based compensation            692        837      3,196      4,264
  Amortization of acquired
   intangible assets                2,019         68      6,668        272
  Merger, restructuring and
   other non-recurring items,
   net                             (6,726)         -     17,723          -
  Income tax adjustments             (760)         -     (8,983)         -
                                ---------  ---------  ---------  ---------

Non-GAAP income (loss) from
 continuing operations
 before non-controlling
 interest                       $   3,364  $  (4,277) $  (8,927) $ (20,101)
                                =========  =========  =========  =========

Loss per share:

Basic
GAAP income (loss) per share
 from continuing operations     $    0.24  $   (0.19) $   (0.80) $   (0.89)

  Stock-based compensation           0.02       0.03       0.09       0.15
  Amortization of acquired
   intangible assets                 0.06          -       0.19       0.01
  Merger, restructuring and
   other non-recurring costs        (0.20)         -       0.52          -
  Income tax adjustments            (0.02)         -      (0.26)         -
                                ---------  ---------  ---------  ---------

Non-GAAP (income) loss per
 share from continuing
 operations before
 non-controlling interest       $    0.10  $   (0.16) $   (0.26) $   (0.73)
                                =========  =========  =========  =========
Diluted
GAAP income (loss) per share
 from continuing operations     $    0.23  $   (0.19) $   (0.80) $   (0.89)

  Stock-based compensation           0.02       0.03       0.09       0.15
  Amortization of acquired
   intangible assets                 0.06          -       0.19       0.01
  Merger, restructuring and
   other non-recurring costs        (0.19)         -       0.52          -
  Income tax adjustments            (0.02)         -      (0.26)         -
                                ---------  ---------  ---------  ---------

Non-GAAP income (loss) per
 share from continuing
 operations before
 non-controlling interest       $    0.10  $   (0.16) $   (0.26) $   (0.73)
                                =========  =========  =========  =========

Weighted average shares
 outstanding:

  Basic                            34,533     27,591     34,369     27,526
                                ---------  ---------  ---------  ---------
  Diluted                          35,279     27,591     34,369     27,526
                                ---------  ---------  ---------  ---------

                           Syneron Medical Ltd.
  Unaudited Pro Forma Condensed Consolidated Statements of Income (Loss)
                  (in thousands, except per share data)

                         For the three months ended December 31, 2009
                    ------------------------------------------------------
                      Syneron       Candela       Pro Forma     Pro Forma
                      Medical     Corporation   Adjustments     Combined
                    ------------  ------------  ------------  ------------

Revenue             $     14,403  $     32,272  $        (87) $     46,588
Cost of sales              4,239        19,227           275        23,741
                    ------------  ------------  ------------  ------------
Gross profit              10,164        13,045          (362)       22,847
Operating expenses:
  Sales and
   marketing               7,869         8,245           968        17,082
  General and
   administrative          3,419         4,027           100         7,546
  Research and
   development             4,271         2,547             -         6,818
                    ------------  ------------  ------------  ------------
Total operating
 expenses                 15,559        14,819         1,068        31,446
                    ------------  ------------  ------------  ------------
Loss from
 operations               (5,395)       (1,774)       (1,430)       (8,599)
Other income:
  Financial Income,
   net                       436            33             -           469
  Other income               562           534             -         1,096
                    ------------  ------------  ------------  ------------
  Total other
   income                    998           567             -         1,565
                    ------------  ------------  ------------  ------------
Loss from
 continuing
 operations before
 income taxes             (4,397)       (1,207)       (1,430)       (7,034)
Expense (benefit)
 from income taxes           785        (1,118)         (520)         (853)
                    ------------  ------------  ------------  ------------
Loss from
 continuing
 operations
 before
 non-controlling
 interest                 (5,182)          (89)         (910)       (6,181)
                    ============  ============  ============  ============

Loss per share:
Basic and diluted
  Loss from
   continuing
   operations
   before
   non-controlling
   interest                                                   $      (0.18)
                                                              ============

Weighted average
 shares
 outstanding:
  Basic and diluted                                                 34,261
                                                              ------------

                           Syneron Medical Ltd.
  Unaudited Pro Forma Condensed Consolidated Statements of Income (Loss)
                  (in thousands, except per share data)

                        For the twelve months ended December 31, 2009
                    ------------------------------------------------------
                      Syneron       Candela       Pro Forma     Pro Forma
                      Medical     Corporation   Adjustments     Combined
                    ------------  ------------  ------------  ------------

Revenue             $     54,726  $    119,655  $       (349) $    174,032
Cost of sales             18,903        73,631         1,370        93,904
                    ------------  ------------  ------------  ------------
Gross profit              35,823        46,024        (1,719)       80,128
Operating expenses:
  Sales and
   marketing              34,156        30,202         3,872        68,230
  General and
   administrative         16,478        15,334           400        32,212
  Research and
   development            13,220         8,970             -        22,190
  Legal settlement,
   net                    (3,975)            -             -        (3,975)
                    ------------  ------------  ------------  ------------
Total operating
 expenses                 59,879        54,506         4,272       118,657
                    ------------  ------------  ------------  ------------
Loss from
 operations              (24,056)       (8,482)       (5,991)      (38,529)
Other income:
  Financial Income,
   net                     2,097           598             -         2,695
  Other income               562           543             -         1,105
                    ------------  ------------  ------------  ------------
  Total other
   income                  2,659         1,141             -         3,800
                    ------------  ------------  ------------  ------------
Loss from
 continuing
 operations before
 income taxes            (21,397)       (7,341)       (5,991)      (34,729)
Expense (benefit)
 from income taxes         3,240        (3,153)       (2,179)       (2,092)
                    ------------  ------------  ------------  ------------
Loss from
 continuing
 operations
 before
 non-controlling
 interest                (24,637)       (4,188)       (3,812)      (32,637)
                    ============  ============  ============  ============

Loss per share:
Basic and diluted
  Loss from
   continuing
   operations
   before
   non-controlling
   interest                                                   $      (0.95)
                                                              ============

Weighted average
 shares
 outstanding:
  Basic and diluted                                                 34,196
                                                              ------------

                           Syneron Medical Ltd.
    Unaudited Pro Forma Non-GAAP Financial Measures and Reconciliation
                  (in thousands, except per share data)

                                          For the three months ended
                                                December 31, 2009
                                     -------------------------------------
                                       Syneron      Candela     Pro Forma
                                       Medical    Corporation    Combined
                                     -----------  -----------  -----------

GAAP operating loss                  $    (5,395) $    (3,204) $    (8,599)

 Stock-based compensation                    837          475        1,312
 Amortization of acquired intangible
  assets                                      68        1,320        1,388
 Merger, restructuring and other
  non-recurring costs                          -          110          110
                                     -----------  -----------  -----------

Non-GAAP operating loss              $    (4,490) $    (1,299) $    (5,789)
                                     ===========  ===========  ===========

GAAP loss from continuing operations $    (5,182) $      (999) $    (6,181)

  Stock-based compensation                   837          475        1,312
  Amortization of acquired intangible
   assets                                     68        1,320        1,388
  Merger, restructuring and other
   non-recurring costs                         -          110          110
  Income tax adjustments                       -         (693)        (693)
                                     -----------  -----------  -----------

Non-GAAP loss from continuing
 operations                          $    (4,277) $       213  $    (4,064)
                                     ===========  ===========  ===========

GAAP loss per share from continuing
 operations                                                    $     (0.18)

  Stock-based compensation                                            0.04
  Amortization of acquired intangible
   assets                                                             0.04
  Merger, restructuring and other
   non-recurring costs                                                   -
  Income tax adjustments                                             (0.02)
                                                               -----------

Non-GAAP loss per share from
 continuing operations                                         $     (0.12)
                                                               ===========

Weighted average shares outstanding:

  Basic and diluted                                                 34,261
                                                               -----------

                           Syneron Medical Ltd.
    Unaudited Pro Forma Non-GAAP Financial Measures and Reconciliation
                  (in thousands, except per share data)

                                         For the twelve months ended
                                                December 31, 2009
                                     -------------------------------------
                                       Syneron      Candela     Pro Forma
                                       Medical    Corporation    Combined
                                     -----------  -----------  -----------

GAAP operating loss                  $   (24,056) $   (14,473) $   (38,529)

  Stock-based compensation                 4,264        2,338        6,602
  Amortization of acquired intangible
   assets                                    272        5,279        5,551
  Merger, restructuring and other
   non-recurring costs                         -          712          712
                                     -----------  -----------  -----------

Non-GAAP operating loss              $   (19,520) $    (6,144) $   (25,664)
                                     ===========  ===========  ===========

GAAP loss from continuing operations $   (24,637) $    (8,000) $   (32,637)

  Stock-based compensation                 4,264        2,338        6,602
  Amortization of acquired intangible
   assets                                    272        5,279        5,551
  Merger, restructuring and other
   non-recurring costs                         -          712          712
  Income tax adjustments                       -       (3,029)      (3,029)
                                     -----------  -----------  -----------

Non-GAAP loss from continuing
 operations                          $   (20,101) $    (2,700) $   (22,801)
                                     ===========  ===========  ===========

GAAP loss per share from continuing
 operations                                                    $     (0.95)

  Stock-based compensation                                            0.19
  Amortization of acquired intangible
   assets                                                             0.16
  Merger, restructuring and other
   non-recurring costs                                                0.02
  Income tax adjustments                                             (0.09)
                                                               -----------

Non-GAAP loss per share from
 continuing operations                                         $     (0.67)
                                                               ===========

Weighted average shares outstanding:

  Basic and diluted                                                 34,196
                                                               -----------

Syneron Contacts:

Asaf Alperovitz
Chief Financial Officer
+ 972 73 244 2283

Nick Laudico/Zack Kubow
The Ruth Group
646-536-7030/7020

Cyanotech’s (CYAN) Spirulina Pacifica(R) May Counter Anemia and Declining Immune Function

Feb. 16, 2011 (Business Wire) — Cyanotech Corporation (Nasdaq Capital Market: CYAN), world leader in microalgae-based health and nutrition supplements, announced today that researchers at the University of California at Davis have determined that microalgae-based Hawaiian Spirulina Pacifica® may improve immune function and ameliorate anemia in persons over 50. Results of the UC Davis study will be published in the March edition of the journal Cellular & Molecular Immunology, in a paper entitled, ”The effects of Spirulina on anemia and immune function in senior citizens.”

Cyanotech produces Hawaiian Spirulina Pacifica, along with other microalgae nutrition supplements, at its 90-acre facility in Kona, Hawaii using patented and proprietary technology. Spirulina Pacifica is a nutrient-rich, highly absorbable source of protein, mixed carotenoids and other phytonutrients, B-Vitamins, GLA and essential amino acids.

Dr. Gerald Cysewski, Cyanotech’s Chief Scientific Officer, said, “We are delighted with the very positive results of the UC Davis Spirulina Pacifica study, and the impact this development can have on the health of the over-50 population. Study researchers are urging that large-scale random clinical trials of Spirulina Pacifica should now be undertaken, and we most definitely concur.”

The Cyanotech Spirulina Pacifica study was conducted by the UC Davis Division of Rheumatology, Allergy and Clinical Immunology under the supervision of Dr. M. Eric Gershwin and scientists from UC Davis. The objective was to determine if Spirulina Pacifica could be effective in countering two conditions that frequently impact the health of older people: anemia and declining immune function.

Thirty participants over the age of 50 took Spirulina Pacifica supplements for 12 weeks. Key blood chemistry markers for immune function were tested at the outset of the study and again after six and 12 weeks. The subjects’ daily dietary regimens were monitored throughout the process.

Dr. Cysewski said, “The research found a steady increase in corpuscular hemoglobin in subjects of both sexes, and improved immune function in the majority of subjects.”

About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology, produces BioAstin® Natural Astaxanthin and Hawaiian Spirulina Pacifica®—all natural, functional nutrients that leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. Cyanotech’s Spirulina products offer complete nutrition, and augment energy and immune response. They are FDA reviewed and accepted as Generally Recognized as Safe (GRAS) for use in food products. BioAstin’s superior antioxidant activity and ability to support and maintain a natural anti-inflammatory response enhance skin, muscle and joint health. All Cyanotech products are produced from microalgae grown at its 90-acre facility in Kona, Hawaii using patented and proprietary technology. Cyanotech distributes to nutritional supplement, nutraceutical and cosmeceutical manufacturers and marketers in more than 54 countries worldwide. Cyanotech was the first microalgae company in the world to obtain quality management standards ISO 9001:2000 certification and is GMP-certified by the Natural Products Association^TM. Visit www.cyanotech.com for more information

Cyanotech Corporation

Bruce Russell

310-559-4955 x101

brussell@cyanotech.com

Threshold Pharmaceuticals (THLD) Announces Agreement With the FDA on a Special Protocol Assessment

REDWOOD CITY, Calif., Feb. 16, 2011 (GLOBE NEWSWIRE) — Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that the Company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 randomized trial of TH-302 in patients with soft tissue sarcoma. This pivotal trial is expected to begin in the middle of 2011, and will enroll patients with metastatic or locally advanced unresectable soft tissue sarcoma who have not previously received chemotherapy outside the adjuvant or neoadjuvant setting. The trial is designed to evaluate the efficacy and safety of TH-302 in combination with doxorubicin, compared to doxorubicin alone.

“With this SPA, we have reached agreement with the FDA on the key features of our Phase 3 trial design that will be necessary to support the registration of TH-302,” said Stewart Kroll, Threshold’s Vice President, Biostatistics and Clinical Operations. “The proposed trial is designed to confirm the encouraging results that we have previously reported in our ongoing Phase 1/2 trial of soft tissue sarcoma patients treated with TH-302 in combination with doxorubicin.”

TH-302 Clinical Development Rationale and Strategy

TH-302 has been investigated in over 400 patients with cancer as part of five clinical trials. The TH-302 clinical development program includes an ongoing Phase 1/2 trial in patients with soft tissue sarcoma. As presented at the Connective Tissue Oncology Society meeting in November 2010, fifty-four patients had at least one evaluable post-treatment tumor assessment and 18 of 54 (33%) had a partial response. The median progression free survival was 6.4 months (95% confidence interval: 5.6 to 6.9 months). These data formed the basis for the proposed Phase 3 study of TH-302 and doxorubicin compared to doxorubicin, as covered by the SPA.

In addition, Threshold is pursuing additional clinical trials in patients with solid tumors as well as hematologic malignancies. TH-302 is currently being evaluated in a Phase 2 randomized, controlled combination trial in patients with metastatic or locally advanced pancreatic cancer as well as a Phase 1 open label, monotherapy trial in patients with advanced leukemias.

About the Phase 3 Sarcoma Trial

The Phase 3 trial will be a 450 patient, randomized, open-label, multi-center trial comparing two treatment regimens for patients with metastatic and/or advanced unresectable soft tissue sarcoma who have not received prior doxorubicin. This trial is designed to demonstrate the clinical benefit of TH-302 in combination with doxorubicin compared to doxorubicin alone based on a primary efficacy endpoint of overall survival. The trial includes an interim analysis based on progression-free survival expected to occur about half-way into enrollment and an interim analysis based on overall survival expected to occur at the end of enrollment. Patients will be randomized to receive TH-302 (300 mg/m² on days 1 and 8 of a 21 day cycle) in addition to the standard dosing schedule of doxorubicin (75 mg/m² on day 1 of the 21 day cycle) compared to doxorubicin alone. The Company plans to commence the trial in the middle of 2011.

About Soft Tissue Sarcoma

Sarcomas are a group of aggressive cancers of connective tissue of the body for which there are currently limited treatment options. Soft tissue sarcomas are treated with surgery, chemotherapy and radiation. Usually a combination of these modalities offers the best chance to treat the disease successfully. Doxorubicin and ifosfamide are the most commonly used chemotherapeutic agents in patients with advanced soft tissue sarcoma, but response rates are generally low and toxicity can be significant. The American Cancer Society estimates that 10,520 people were diagnosed with a soft tissue sarcoma in the United States in 2010, and approximately 3,920 people died from the disease.

About Special Protocol Assessments

A Special Protocol Assessment is a written agreement with the FDA on the design and planned analysis for a clinical trial. It is intended to form the basis for a marketing application and may only be changed through a written agreement between the sponsor and the FDA, or if the FDA becomes aware of new public health concerns.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding TH-302 and its potential therapeutic uses and benefits. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold’s ability to raise sufficient funding to conduct the Phase 3 trial of TH-302 for patients with soft tissue sarcoma and to successfully enroll patients in that trial as well as the ongoing clinical trials of TH-302, whether the Company’s clinical trials will show results predicted by the Company’s pre-clinical trials or confirm the results of earlier trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and any unanticipated or increased side-effects observed in patients receiving TH-302. Further information regarding these and other risks is included under the heading “Risk Factors” in Threshold’s Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on November 4, 2010 and is available from the SEC’s website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading “Investors.” We do not intend to update any forward-looking statement made in this news release.

CONTACT: Denise T. Powell
         Sr. Director, Corporate Communications
         Threshold Pharmaceuticals, Inc.
         650-474-8206
         dpowell@thresholdpharm.com

GlobalSCAPE(R) (GSB) Expands Cloud Services with Launch of GlobalSCAPE Hosted Enhanced File Transfer Server

Feb. 15, 2011 (Business Wire) — GlobalSCAPE, Inc. (NYSE Amex: GSB), a leading developer of secure information exchange solutions, announced today immediate availability of a new hosted managed file transfer (MFT) solution, GlobalSCAPE Hosted Enhanced File Transfer Server™. This new service expands the company’s cloud-based Managed Solutions, launched in July 2010, by integrating a hosted version of its market-leading Enhanced File Transfer Server^® (EFT Server) solution with proven infrastructure from Rackspace^® Hosting (NYSE: RAX), the world’s leading specialist in the hosting and cloud computing industry.

GlobalSCAPE’s Hosted EFT Server enables organizations to securely exchange business-to-business data, including large files and sensitive data, through the cloud. This scalable and tiered service is ideal for the small-to-medium (SMB) market, and also allows customers of all sizes to outsource all or part of their complex and demanding secure information exchange needs. Through such outsourcing, customers can greatly reduce costs, increase efficiencies, track and audit transactions, and provide a greater level of security and compliance, at affordable price points.

The Hosted EFT Server offering delivers these benefits while allowing direct customer management of the EFT Server solution. GlobalSCAPE also offers a fully managed solution, Managed Information Xchange (MIX), for companies seeking complete support.

“Many organizations are embracing cloud computing to save money and to increase efficiency and business agility,” said Mark Perry, vice president of managed solutions at GlobalSCAPE. “This new service will be very attractive to SMB customers who are looking for high-end managed file transfer capabilities delivered securely through a cloud-based infrastructure at an affordable price.”

Key benefits and features of the new offering include:

• Market-leading features and security capabilities of GlobalSCAPE’s EFT Server solution adopted by thousands of customers worldwide
• Robust MFT features including management, automation, and auditing of all file transfer activity for meeting security and compliance mandates
• “Pay as you go” flexible and affordable pricing that helps customers eliminate upfront capital expenditures
• Reduced ongoing maintenance expenses, including hardware, software, and utility services costs
• Deployed rapidly to meet time-sensitive business demands
• Reliable and timely support from GlobalSCAPE’s support team

GlobalSCAPE is discussing Hosted EFT Server and the growth of cloud computing this week at the 2011 RSA Conference (Booth #2159) in San Francisco, February 14 – 18. The annual RSA Conference brings together key players, companies, and potential customers from the information security industry.

To learn more about GlobalSCAPE Hosted EFT Server, including features and benefits, please visit the company website.

In addition to GlobalSCAPE Hosted Enhanced File Transfer Server, GlobalSCAPE also announced the development of appShield™, an innovative new computer security product for home and small business computers. With appShield, GlobalSCAPE is pioneering a much needed safeguard to protect computers against the rapid growth of viruses and other malicious software. appShield is based on proven enterprise-level application whitelisting technology from CoreTrace Corporation, the recognized leader in dynamic and client-based application whitelisting. For more information about GlobalSCAPE and its announcements at the event, please visit the digital press room.

About GlobalSCAPE

GlobalSCAPE, Inc. (NYSE Amex: GSB), headquartered in San Antonio, TX, is a global solutions provider that equips organizations to securely exchange sensitive information and files across multiple locations and with customers and partners. Since the release of CuteFTP in 1996, GlobalSCAPE’s solutions have continued to evolve to meet the business and technology needs of an increasingly interconnected global marketplace. Serving a customer base that spans more than 150 countries and includes the majority of Fortune 100 companies, GlobalSCAPE’s primary focus is providing customers with intuitive and efficient managed file transfer (MFT) solutions while also ensuring end-to-end security. For more information, visit www.globalscape.com, or subscribe to our Blog and Twitter updates.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “would,” “exceed,” “should,” “anticipates,” “believe,” “steady,” “dramatic,” and variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s Annual Report on Form 10-K for the 2009 calendar year, filed with the Securities and Exchange Commission on March 30, 2010.

New Venture Communications

Lauren Dresnick, 650-740-4034

ldresnick@newventurecom.com

Cynosure (CYNO) Reports Financial Results for the Fourth Quarter of 2010

WESTFORD, Mass., Feb. 15, 2011 /PRNewswire/ — Cynosure, Inc. (Nasdaq: CYNO) today announced financial results for the three months and year ended December 31, 2010.

Revenues for the fourth quarter of 2010 increased 16 percent to $22.3 million from $19.3 million in the same period of 2009.   Net loss for the fourth quarter of 2010 was $0.8 million, or $0.06 per basic and diluted share, compared with a net loss of $14.5 million, or $1.14 per basic and diluted share, or the comparable period of 2009.  Financial results for the fourth quarter of 2009 included a non-cash tax charge of $10.4 million to establish a valuation allowance against the company’s U.S. deferred tax assets, and a $2.1 million non-cash charge related to an inventory write-down of an earlier-generation product.

The company reduced its loss from operations in the fourth quarter of 2010 to $0.6 million, which included stock-based compensation of approximately $0.6 million.  This compares with a loss from operations in the fourth quarter of 2009 of $5.7 million, which included stock-based compensation of $1.1 million.

“Higher product demand from North America and overseas drove our revenue growth in the fourth quarter,” said Cynosure President and Chief Executive Officer Michael Davin.  “In North America, laser product sales were up 17 percent from the same period in 2009.  Although financing remains difficult for many aesthetic practitioners, the relationships we have established with certain financial institutions and third-party financing sources are gradually beginning to improve access to credit for our customers.  International laser product sales rose 18 percent from the fourth quarter of 2009, paced by solid gains in our Asian direct distribution network.”

Gross profit for the fourth quarter of 2010 was 55.9 percent of total revenues, compared with 43.9 percent for the same period of 2009, which included the inventory write-down. The improvement in gross margin in the 2010 period reflected the effects of the inventory write-down as well as a higher percentage of sales from direct distribution channels, which carry higher margins than products sold through third-party distributors.

Total operating expenses for the fourth quarter of 2010 decreased $1.1 million, or 8 percent, to $13.1 million from $14.2 million for the same period of 2009.  For full-year 2010, total operating expenses decreased $8.9 million, or 15 percent, to $51.4 million from $60.3 million for 2009.

“We generated positive cash flow from operations for the seventh consecutive quarter in Q4, reflecting the success of our cost-reduction initiatives,” Davin said. “With our $8.9 million decrease in operating expenses for the year, we exceeded our goal of lowering annualized operating expenses in the range of $5 million to $7 million from 2009, and also exceeded our objective to be cash-flow breakeven for 2010. Our cash, marketable securities and investments totaled $96.8 million at year-end, an increase of approximately $4.9 million from the end of 2009. We also purchased $1.4 million of stock under our previously announced stock buyback plan in 2010.”

FY 2010 Financial Results:  Year-over-Year Revenue Growth of 12 Percent

Revenues for the 12 months ended December 31, 2010 increased 12 percent to $81.8 million from $72.8 million for the full year of 2009.  Gross profit for 2010 was 56.7 percent of total revenues, compared with 54.9 percent for 2009, which included the inventory write-down.  Net loss for 2010 was $5.5 million, or $0.44 per basic and diluted share, compared with a net loss for full-year 2009 of $22.8 million, or $1.79 per basic and diluted share. Financial results for 2009 included the non-cash tax charge of $10.4 million to establish a valuation allowance against the company’s U.S. deferred tax assets, and the $2.1 million non-cash charge related to an inventory write-down of an earlier-generation product.

Recent Highlights

• World’s First Minimally Invasive Laser for Long-term Cellulite Reduction: Cynosure recently introduced the Cellulaze™ Cellulite Laser Workstation, the world’s first minimally invasive surgical device specifically designed for the long-term reduction of cellulite.   Cellulaze uses laser energy to restore the normal structure of the skin and underlying connective tissue, increasing skin elasticity and thickness.  The product, which recently received CE Mark certification, was unveiled this month at the American Academy of Dermatology’s 69th Annual Meeting in New Orleans. It will be available for sale to physicians in the European Union in the second quarter of 2011.
• Non-Invasive SmoothShapes XV for Temporary Reduction of Cellulite: Cynosure acquired substantially all of the assets of Eleme Medical, including the company’s non-invasive SmoothShapes® XV system for the temporary reduction in the appearance of cellulite. The SmoothShapes XV system treats cellulite through a proprietary process known as Photomology®, which combines laser and light energy with mechanical manipulation (vacuum and massage) to produce tighter, smoother-looking skin. The system is FDA cleared for marketing in the United States and CE marked for sale in the European Union.

“Product innovation is the engine that continues to drive growth at Cynosure, and we believe that our new cellulite workstations will play an integral role in the company’s long-term success,” Davin said. “In Cellulaze and SmoothShapes XV, we are building a broad technology platform designed to serve practitioners and their patients who are seeking a solution for either long-lasting or temporary cellulite reduction.  We are excited about the future potential of these products to treat what we believe is a significantly underserved aesthetic indication that affects 85 percent of women over the age of 20.”

Outlook

“Our strong balance sheet and aggressive cost-reduction initiatives put us on solid financial footing for the coming year, as we focus on building momentum across our direct and third-party distributor sales,” Davin said. “Near-term, we plan to begin rolling out Cellulaze in key European territories, complete the clinical steps necessary for regulatory review of our Cellulaze 510(k) application in the United States and launch our SmoothShapes XV workstation in domestic and international markets.  We are optimistic about the prospects for our business in 2011.”

Fourth-Quarter and Year-End Financial Results Conference Call

In conjunction with its fourth-quarter results, Cynosure will host a conference call for investors and analysts at 9:00 a.m. ET today.  On the call, Michael Davin and Timothy Baker, the company’s Executive Vice President and Chief Financial Officer, will discuss the company’s financial results and provide a business overview. Those who wish to listen to the conference call webcast should visit the “Investor Relations” section of the company’s website at www.cynosure.com.  The live call can also be accessed by dialing (877) 407-5790 or (201) 689-8328.  If you are unable to listen to the live call, the webcast will be archived on the company’s website.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and reduce the appearance of cellulite.  Cynosure’s products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.  For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company’s anticipated financial results, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economy and lending environment and their effects on the aesthetic laser industry, Cynosure’s history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission.  In addition, the forward-looking statements included in this press release represent Cynosure’s views as of the date of this press release.  Cynosure anticipates that subsequent events and developments will cause its views to change.  However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing Cynosure’s views as of any date subsequent to the date of this press release.